SELFEMRA (fluoxetine hydrochloride) by Teva is unknown, it is presumed to be linked to its inhibition of cns neuronal uptake of serotonin. Approved for depressive episodes associated with bipolar i disorder, the treatment of treatment resistant depression, depression. First approved in 2014.
Drug data last refreshed 20h ago
unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
Worked on SELFEMRA at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Under Fasting Condition
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition
90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions
To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg